RECANA OUS - Recana Thrombectomy Catheter System for Venous Obstruction and Occlusion Study (RECA… (NCT07095660) | Clinical Trial Compass
RecruitingNot Applicable
RECANA OUS - Recana Thrombectomy Catheter System for Venous Obstruction and Occlusion Study (RECANA-OUS-IRL)
Ireland20 participantsStarted 2025-07-02
Plain-language summary
The goal of this clinical investigation is to learn if the Recana Thrombectomy Catheter System can treat chronic venous obstruction and occlusion in participants with symptomatic post-thrombotic venous inflow/outflow obstruction. The main questions the clinical investigation aims to answer are:
1. primary safety endpoint: procedural events defined as the rates of all adverse events occurring up to 30 days post-index procedure
2. primary efficacy endpoint: percent (%) lumen gain during the index procedure, which is measured using intravascular ultrasound (IVUS) at the time of the procedure (perioperative/periprocedural)
Participants are screened and qualified for the clinical investigation. Qualified participants (those that meet all eligibility criteria) will undergo treatment with the Recana Thrombectomy Catheter System. Participants are assessed at the following timepoints: 30, 90, 180 and 365 days post-procedure.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Provision of signed and dated informed consent form;
✓. Participant is 18 years of age and older;
✓. Neurologically stable;
✓. Ambulatory;
✓. Symptomatic chronic venous insufficiency (CVI), with edema or pain, (CEAP classification of C3 or greater);
✓. Flow-limiting venous outflow obstruction (\>50%) within the intended target sites, defined by (a) a common femoral vein continuous waveform without respiratory variation on duplex ultrasound, or, (b) complete occlusion of any part of the iliofemoral tract as diagnosed on baseline duplex or axial imaging per local protocol; and
✓. Target treatment IVC/Common Iliac confluence to the deep veins above the knee.
Exclusion criteria
✕. Comorbidity risks which may limit longevity (\<2 years life expectancy), would preclude open surgery, or would significantly increase risk for venous thrombo-embolism (VTE);
✕
What they're measuring
1
Primary Safety Endpoint - Rates of all Adverse Events through 30-days post-index procedure
Timeframe: 30-days post-procedure
2
Primary Efficacy Endpoint - Percent Lumen Gain in the Treated Vessel measured at time of procedure
. Invasive abdominal, pelvic or peripheral vascular surgery within 90 days of the procedure;
✕. History of stroke within the last 6 months;
✕. Known hypercoagulable states that, in the opinion of the Investigator, cannot be medically-managed throughout the study period (i.e., known thrombophilia) including Heparin-induced thrombocytopenia (HIT) and antiphospholipid syndrome (APS);
✕. Interventional procedure in the deep venous system (including stent placement) in the target limb or outflow vessels within 6 weeks of consent;
✕. Acute deep venous thrombosis (DVT) in the index limb (not previously observed in the thrombus bearing segment) within 3 months of consent;
✕. Inadequate inflow in the opinion of the investigator, that cannot be improved to the target vessel;
✕. Flow-limiting venous outflow obstruction central to the target/treatment vessel that cannot be treated;